STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug zanzalintinib tested for advanced liver cancer
Disease control Recruiting nowThis study tests a drug called zanzalintinib in people with advanced liver cancer that has spread or cannot be cured. The trial has two parts: first, finding the safest dose, then checking if it helps control the cancer. About 59 participants will take the drug by mouth, and rese…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Devalingam Mahalingam • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for advanced liver cancer: radiation boosts immunotherapy in major trial
Disease control Recruiting nowThis phase 3 trial is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs (atezolizumab and bevacizumab) alone versus the same drugs plus targeted radiation (SBRT). The goal is to see if adding radiation helps pa…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug AU409 enters first human trial for tough liver cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could your own immune cells fight liver cancer? new trial aims to find out
Disease control Recruiting nowThis study tests a new approach for people with advanced liver cancer that cannot be surgically removed. Participants receive radiation followed by an injection of their own specially trained immune cells (dendritic cells), a pneumonia vaccine to boost immunity, and immunotherapy…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cocktail targets untreatable liver cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Could a painkiller boost immunotherapy in liver cancer?
Disease control Recruiting nowThis phase 2 trial tests whether adding celecoxib (a painkiller) to two immunotherapy drugs (durvalumab and tremelimumab) can help control advanced or metastatic liver cancer. About 39 adults with liver cancer that has spread will receive the combination. The goal is to see if it…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Electric field device combined with drugs tested for advanced cancers
Disease control Recruiting nowThis early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo aims to boost immune attack on liver tumors after radiation
Disease control Recruiting nowThis phase II trial tests whether giving immune-boosting drugs (durvalumab with or without tremelimumab) after standard radiation can shrink advanced liver cancer that has spread. About 21 adults whose cancer has progressed on or after prior immunotherapy will receive radiation f…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Can radiation kickstart the immune system against stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New combo therapy aims to outsmart advanced liver cancer
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug atezolizumab to a targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. The study enrolls 122 adults whose…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 26, 2026 18:19 UTC
-
New microscope peers inside living tumors to see how they behave
Knowledge-focused Recruiting nowThis study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC